IN2012DN00167A - - Google Patents

Info

Publication number
IN2012DN00167A
IN2012DN00167A IN167DEN2012A IN2012DN00167A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A IN 167DEN2012 A IN167DEN2012 A IN 167DEN2012A IN 2012DN00167 A IN2012DN00167 A IN 2012DN00167A
Authority
IN
India
Prior art keywords
treatment
compositions
concerned
methods
multiple sclerosis
Prior art date
Application number
Other languages
English (en)
Inventor
B Gelder Frank
Alison Webster Gillian
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of IN2012DN00167A publication Critical patent/IN2012DN00167A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photographic Developing Apparatuses (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN167DEN2012 2009-06-16 2010-06-16 IN2012DN00167A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
IN2012DN00167A true IN2012DN00167A (pl) 2015-04-17

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
IN167DEN2012 IN2012DN00167A (pl) 2009-06-16 2010-06-16

Country Status (20)

Country Link
US (1) US8389479B2 (pl)
EP (1) EP2442832B1 (pl)
JP (1) JP5646617B2 (pl)
CN (1) CN102458476B (pl)
AU (1) AU2010260585B2 (pl)
BR (1) BRPI1009606A2 (pl)
CA (1) CA2688766C (pl)
CY (1) CY1115714T1 (pl)
DK (1) DK2442832T3 (pl)
ES (1) ES2521565T3 (pl)
HR (1) HRP20141035T1 (pl)
IL (1) IL216993A (pl)
IN (1) IN2012DN00167A (pl)
MX (1) MX2011013661A (pl)
NZ (1) NZ577731A (pl)
PL (1) PL2442832T3 (pl)
PT (1) PT2442832E (pl)
SI (1) SI2442832T1 (pl)
SM (1) SMT201400165B (pl)
WO (1) WO2010147484A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2268289A4 (en) * 2008-04-01 2014-07-02 Innate Therapeutics Ltd ANTI-INFECTIVES AND USES THEREOF
EP3326645B1 (en) * 2010-10-25 2020-03-18 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
AU2016202146A1 (en) * 2015-10-06 2017-04-20 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
US12109271B2 (en) 2018-07-03 2024-10-08 University Of Florida Research Foundation, Incorporated Microparticle systems and their use for the treatment of multiple sclerosis
KR20230028765A (ko) * 2020-06-22 2023-03-02 오티비오 에이에스 항경직성 조성물 및 음압 요법을 사용하여 경직을 치료하는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502315A (ja) * 1996-10-10 2001-02-20 プローブ・インターナショナル ウイルス感染を処置するための組成物および方法
JP2008505130A (ja) * 2004-07-01 2008-02-21 ケベンハウンス・ウニヴェルジテート レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Also Published As

Publication number Publication date
DK2442832T3 (da) 2014-11-10
CN102458476A (zh) 2012-05-16
WO2010147484A1 (en) 2010-12-23
HK1167101A1 (en) 2013-02-01
EP2442832A1 (en) 2012-04-25
SI2442832T1 (sl) 2014-12-31
NZ577731A (en) 2010-08-27
IL216993A0 (en) 2012-02-29
US20100317589A1 (en) 2010-12-16
AU2010260585A8 (en) 2012-06-14
CN102458476B (zh) 2014-08-20
CA2688766A1 (en) 2010-12-16
HRP20141035T1 (hr) 2014-12-19
AU2010260585A1 (en) 2012-01-19
CY1115714T1 (el) 2017-01-25
EP2442832A4 (en) 2013-07-03
CA2688766C (en) 2015-06-30
US8389479B2 (en) 2013-03-05
BRPI1009606A2 (pt) 2016-10-11
IL216993A (en) 2016-03-31
PT2442832E (pt) 2014-11-11
WO2010147484A8 (en) 2012-07-19
JP5646617B2 (ja) 2014-12-24
SMT201400165B (it) 2015-01-15
EP2442832B1 (en) 2014-08-06
MX2011013661A (es) 2012-05-22
JP2012530132A (ja) 2012-11-29
PL2442832T3 (pl) 2015-01-30
AU2010260585B2 (en) 2013-02-21
ES2521565T3 (es) 2014-11-12

Similar Documents

Publication Publication Date Title
IN2012DN00167A (pl)
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
IN2012DN03883A (pl)
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
PH12014500053A1 (en) Proteasome inhibitors
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
IN2012DN00971A (pl)
JO2860B1 (en) Phenylendazolyl compounds
GB0920703D0 (en) Compositions containing satiogens and methods of use
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2011008179A (es) Peptidos para vacuna.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
MX336742B (es) Inhibidores de amida hidrolasa de acido graso.
EP2566485A4 (en) IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
IN2014DN00254A (pl)
PH12012501963A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MX2011010046A (es) Derivados de diaminopteridina.
PH12013500743A1 (en) Elastometric dental floss
GEP20146006B (en) Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3- dimethyl-butyramide
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
UA42373U (en) Use of taurin and jacton as antioxidant and genome protector
GB0921929D0 (en) Compositions and methods for the treatment of influenza